Home News Ocrelizumab and Rituximab Demonstrate Similar Safety, Efficacy in Treatment of Multiple Sclerosis back to News
minute read
In a comparative study of middle-aged patients with multiple sclerosis (MS) on rituximab (Rituxan; Genentech) and ocrelizumab (Ocrevus; Genentech), findings showed similar safety and efficacy over a 2-year period.
Topics: Press Coverage
13001 East 17th Place
Aurora, CO 80045
303.724.5375
© 2024 The Regents of the University of Colorado, a body corporate. All rights reserved.
Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.
